Total Payments
$18,826
2024 Payments
$670.14
Companies
49
Transactions
179
Medicare Patients
4,645
Medicare Billing
$554,623
Payment Breakdown by Category
Consulting$9,643 (51.2%)
Research$4,312 (22.9%)
Food & Beverage$3,373 (17.9%)
Travel$998.47 (5.3%)
Education$299.44 (1.6%)
Other$200.00 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,643 | 8 | 51.2% |
| Unspecified | $4,312 | 4 | 22.9% |
| Food and Beverage | $3,373 | 157 | 17.9% |
| Travel and Lodging | $998.47 | 4 | 5.3% |
| Education | $299.44 | 5 | 1.6% |
| Honoraria | $200.00 | 1 | 1.1% |
Payments by Type
General
$14,514
175 transactions
Research
$4,312
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $4,312 | 4 | $0 (2020) |
| Puma Biotechnology, Inc. | $3,626 | 6 | $0 (2018) |
| BeiGene USA, Inc. | $2,800 | 2 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,620 | 10 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $1,048 | 2 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $936.67 | 3 | $0 (2024) |
| BeiGene, Ltd. | $525.00 | 1 | $0 (2021) |
| EMD Serono, Inc. | $512.00 | 2 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $338.73 | 16 | $0 (2024) |
| Janssen Biotech, Inc. | $251.76 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $670.14 | 33 | Janssen Biotech, Inc. ($95.41) |
| 2023 | $4,990 | 49 | BeiGene USA, Inc. ($2,275) |
| 2022 | $2,331 | 29 | Janssen Scientific Affairs, LLC ($1,048) |
| 2021 | $1,180 | 12 | BeiGene, Ltd. ($525.00) |
| 2020 | $165.70 | 5 | Astellas Pharma US Inc ($75.99) |
| 2019 | $3,417 | 11 | Eli Lilly and Company ($3,283) |
| 2018 | $5,792 | 23 | Puma Biotechnology, Inc. ($3,626) |
| 2017 | $280.38 | 17 | Janssen Biotech, Inc. ($45.36) |
All Payment Transactions
179 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $19.28 | General |
| 12/05/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo, Tecentriq | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: BioOncology | ||||||
| 11/19/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $14.32 | General |
| Category: Oncology | ||||||
| 10/31/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $31.57 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: BioOncology | ||||||
| 08/22/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: Rare Disease | ||||||
| 08/06/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $15.82 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $20.13 | General |
| 07/18/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: Oncology | ||||||
| 06/18/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: NONE | ||||||
| 06/06/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: Oncology | ||||||
| 06/04/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $28.26 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 05/16/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: Oncology | ||||||
| 05/09/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.92 | General |
| Category: Hematology | ||||||
| 05/02/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $24.13 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 04/25/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: DESMOID TUMORS | ||||||
| 04/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: Oncology | ||||||
| 04/04/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $32.18 | General |
| Category: Oncology | ||||||
| 03/21/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: Oncology | ||||||
| 03/19/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: Oncology | ||||||
| 03/07/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $4,312 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,079 | 2,047 | $435,085 | $135,533 |
| 2022 | 12 | 1,048 | 1,947 | $408,343 | $126,540 |
| 2021 | 11 | 1,104 | 2,185 | $432,068 | $141,022 |
| 2020 | 11 | 1,414 | 2,494 | $472,090 | $151,528 |
Total Patients
4,645
Total Services
8,673
Medicare Billing
$554,623
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 209 | 632 | $138,541 | $44,326 | 32.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 355 | 534 | $81,688 | $22,630 | 27.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 101 | 361 | $62,087 | $21,465 | 34.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 69 | 103 | $28,493 | $10,742 | 37.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 52 | 60 | $28,290 | $7,912 | 28.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 53 | 53 | $20,268 | $7,204 | 35.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 69 | 73 | $24,021 | $6,986 | 29.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 34 | 63 | $18,480 | $5,661 | 30.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 32 | 32 | $9,519 | $2,993 | 31.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 42 | 72 | $11,528 | $2,730 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 36 | 37 | $8,066 | $2,474 | 30.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 27 | 27 | $4,104 | $410.79 | 10.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 193 | 608 | $132,653 | $42,444 | 32.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 392 | 621 | $94,392 | $26,744 | 28.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 86 | 238 | $40,058 | $12,869 | 32.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 76 | 85 | $39,215 | $12,624 | 32.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 72 | 94 | $25,850 | $9,524 | 36.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 54 | 54 | $20,520 | $7,129 | 34.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 27 | 59 | $16,865 | $4,633 | 27.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 39 | 43 | $13,820 | $4,461 | 32.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 34 | 34 | $10,098 | $3,139 | 31.1% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 49 | 71 | $10,811 | $2,073 | 19.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 11 | 11 | $2,640 | $706.20 | 26.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Facility | 2022 | 15 | 29 | $1,421 | $193.34 | 13.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 203 | 624 | $136,037 | $45,769 | 33.6% |
About Dr. Rajesh Bajaj, M.D
Dr. Rajesh Bajaj, M.D is a Hematology & Oncology healthcare provider based in Florence, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972543643.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rajesh Bajaj, M.D has received a total of $18,826 in payments from pharmaceutical and medical device companies, with $670.14 received in 2024. These payments were reported across 179 transactions from 49 companies. The most common payment nature is "Consulting Fee" ($9,643).
As a Medicare-enrolled provider, Bajaj has provided services to 4,645 Medicare beneficiaries, totaling 8,673 services with total Medicare billing of $554,623. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Florence, SC
- Active Since 06/08/2006
- Last Updated 01/03/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1972543643
Products in Payments
- Nerlynx (Drug) $3,626
- BRUKINSA (Drug) $3,325
- DARZALEX (Drug) $1,010
- Stivarga (Drug) $900.00
- Tepmetko (Drug) $500.00
- Pomalyst (Drug) $207.63
- DARZALEX (Biological) $149.33
- KISQALI (Drug) $140.91
- General - Vascular Access (Device) $107.69
- Da Vinci Surgical System (Device) $95.40
- KEYTRUDA (Biological) $90.37
- FARXIGA (Drug) $87.50
- PADCEV (Biological) $78.30
- ZEJULA (Drug) $56.53
- OPDIVO (Biological) $55.08
- VERZENIO (Drug) $53.44
- CYRAMZA (Drug) $50.31
- Xtandi (Drug) $50.29
- ULTOMIRIS (Biological) $43.11
- Revlimid (Drug) $42.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Florence
Dr. Mark Keaton, M.d, M.D
Hematology & Oncology — Payments: $30,744
Hematology & Oncology $30,744
Dr. Clint Kingsley, Md, MD
Hematology & Oncology — Payments: $21,594
Hematology & Oncology $21,594
Dr. Heather Brody
Hematology & Oncology — Payments: $10,048
Hematology & Oncology $10,048
Ravneet Bajwa, M.d, M.D
Hematology & Oncology — Payments: $4,477
Hematology & Oncology $4,477
Dr. Anthony Kalliath, Md, MD
Hematology & Oncology — Payments: $2,727
Hematology & Oncology $2,727
James Smith, Md, MD
Hematology & Oncology — Payments: $2,684
Hematology & Oncology $2,684